NEWARK, DE / ACCESSWIRE / April 12, 2023 / Between 2023 and 2033, the demand for herpes labialis treatments market is anticipated to develop at a CAGR of 4.7%. According to FMI, the size of the global herpes labialis treatment market might increase from US$ 1.13 billion in 2023 to US$ 1.79 billion by 2033.
Herpes simplex virus infections, such as oral herpes and genital herpes, are becoming more prevalent, which is the factor responsible for the increase. Herpes labialis ranks as one of the highly prevalent types of the herpes virus. In addition, the virus is unintentionally contracted and is highly infectious and transmittable by saliva.
The pharmaceutical business is expanding and innovating, which opens up new opportunities for the production of herpes labialis medications. The demand for efficient therapies has increased as people are becoming more aware of the dangers and problems associated with herpes labialis infection. Thus, there is now a higher rate of herpes labialis infection screening and diagnosis, which is boosting market expansion.
For Details on Vendors and Their Offerings - Request A Sample Report: https://www.futuremarketinsights.com/reports/sample/rep-gb-6461
Companies are being encouraged to engage in the development of novel and innovative medications by rising global health expenditures and government assistance to fulfill the growing need for effective therapies.
The possibilities for treating herpes labialis infection have increased as a result of improvements in the development of new antiviral medications. The demand for alternative treatment choices rises as a result of the fact that these new medicines are frequently efficient and cause fewer negative effects.
Herpes labialis infection is currently incurable, and available therapies mainly aim to alleviate symptoms and lessen the frequency and intensity of outbreaks. As a result, there is a sizable unmet clinical requirement in the herpes labialis treatment market. This has sparked the development of novel medications and increased demand for potent solutions.
The herpes labialis treatment market was dominated by North America in 2022 and is predicted to continue to lead over the projected period. The market is expanding due to the presence of numerous significant companies and improvements in technologies for producing medications.
Key Takeaways
- The herpes labialis treatment market in North America was dominated by the United States in 2022, with a share of around 92%.
- From 2023 to 2033, the China herpes labialis treatment market is projected to inflate at a CAGR of 6.1%.
- In 2022, Germany accounted for about 22% of the herpes labialis treatment market in Western Europe.
- Throughout the projection period, the acyclovir segment is anticipated to thrive at a CAGR of 5.1%.
- In terms of distribution, the hospitals segment owned a 35.4% market share in 2022.
Ask More About This Market's Geographical Distribution Along With a Detailed Analysis of the Top Regions@ https://www.futuremarketinsights.com/ask-question/rep-gb-6461
Competitive Landscape
The herpes labialis treatment market is highly competitive, and market players are developing new items to tighten their hold on the market by using several technical advancements. In addition, companies are using strategies like mergers, collaborations, and acquisitions to gather assets that could also enable them to dominate the global market.
Key Companies
- Novartis AG
- Valeant Pharmaceuticals International Inc. (Bausch Health)
- Teva Pharmaceuticals Industries Ltd.
- Bayer AG
- Sun Pharmaceuticals
- Abbott Laboratories
- Amneal Pharmaceuticals, LLC
- Mylan N.V.
- Pfizer Inc.
- GlaxoSmithKline PLC.
- Dr. Reddy's Laboratories
- GC Biopharma Inc
Recent Developments
- Laboratoire Boreaderme Inc. and Ecogene 21 declared in September 2020 that they are working together to execute Phase 2 clinical studies. As open-label research to evaluate the safety profile of BOR15001L7 to docosanol 10% for the management of cold sores in people suffering recurrent herpes labialis.
- Zydus Cadila acquired official FDA clearance in March 2019 to commercialize Acyclovir Ointment USP (US RLD Zovirax), 5%. The first onset of genital herpes is treated with this medication. Those with weakened immune systems can also use it to treat lip and skin herpes infections that are not life-threatening.
Browse Detail Summary Of Research Report@ https://www.futuremarketinsights.com/reports/herpes-labialis-treatment-market
Herpes Labialis Treatment Industry Segmentation
By Drug Type:
- Acyclovir
- Valacyclovir
- Penciclovir
- Famciclovir
- Docosanol
By Route of Administration:
- Oral
- Topical
- Combination
By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Drug Stores
- Online Pharmacies
Table of Content
1. Executive Summary | Herpes Labialis Treatment Market
1.1. Global Market Outlook
1.2. Demand-side Trends
1.3. Supply-side Trends
1.4. Technology Roadmap Analysis
1.5. Analysis and Recommendations
2. Market Overview
2.1. Market Coverage / Taxonomy
2.2. Market Definition / Scope / Limitations
Buy Now to Gain Access to Detailed Information About Each Segment and Identify Key Trends, Drivers, and Challenges in the Market@ https://www.futuremarketinsights.com/checkout/6461
Have a Look at Related Reports of the Healthcare domain
Orthopedic Prosthetic Devices Market Size: The orthopedic prosthetic devices market is projected to register a CAGR of 4.7% during the forecast period, up from US$ 1.9 Bn in 2019 to reach a valuation of US$ 2.8 Bn by 2027.
China Spinal Fusion Market Share: The China spinal fusion market is expected to register double-digit growth during the forecast period.
Cardiac Rhythm Management Market Trends: The global cardiac rhythm management market is expected to grow at a CAGR of 4% during the forecast year 2022 to 2032 from US$ 22.1 Bn in 2021 to US$ 26.8 Bn in 2025.
Cataract Surgery Devices Market Growth: The cataract surgery devices market was valued at US$ 7.4 billion in 2020, and is predicted to advance at a CAGR of 5% from 2022 to 2032.
Skin Replacement Market Forecast: The skin replacement market share is expected to increase at a 6.4 percent CAGR from US$ 838.0 million in 2018 to US$ 1,202.2 million in 2024.
About Future Market Insights (FMI)
Future Market Insights (FMI) is a leading provider of market intelligence and consulting services, serving clients in over 150 countries. FMI is headquartered in Dubai and has delivery centers in the UK, US, and India. FMI's latest market research reports and industry analysis help businesses navigate challenges and make critical decisions with confidence and clarity amidst breakneck competition. Our customized and syndicated market research reports deliver actionable insights that drive sustainable growth. A team of expert-led analysts at FMI continuously tracks emerging trends and events in a broad range of industries to ensure that our clients prepare for the evolving needs of their consumers.
Contact Us:
Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware - 19713, USA
T: +1-845-579-5705
LinkedIn| Twitter| Blogs | YouTube
For Sales Enquiries: [email protected]
SOURCE: Future Market Insights, Inc.